CytomX Therapeutics, Inc.
CTMX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $526,364 | $293,001 | $55,392 | $82,503 |
| - Cash | $34,185 | $49,041 | $47,604 | $38,052 |
| + Debt | $5,596 | $6,885 | $8,149 | $9,385 |
| Enterprise Value | $497,775 | $250,845 | $15,937 | $53,836 |
| Revenue | $5,963 | $18,658 | $50,917 | $38,093 |
| % Growth | -68% | -63.4% | 33.7% | – |
| Gross Profit | $5,963 | $18,658 | $50,917 | $38,093 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$14,037 | -$939 | $23,006 | $18,092 |
| % Margin | -235.4% | -5% | 45.2% | 47.5% |
| Net Income | -$14,229 | -$154 | $23,525 | $18,876 |
| % Margin | -238.6% | -0.8% | 46.2% | 49.6% |
| EPS Diluted | -0.09 | -0.001 | 0.27 | 0.24 |
| % Growth | -7,400% | -100.4% | 12.5% | – |
| Operating Cash Flow | -$15,548 | -$15,753 | -$21,043 | -$19,908 |
| Capital Expenditures | $127 | -$27 | -$119 | -$80 |
| Free Cash Flow | -$15,421 | -$15,780 | -$21,162 | -$19,988 |